semaj83/ctmatch_classification huggingface dataset:
Patient description: A 2-year-old boy is brought to the emergency department by his parents for 5 days of high fever and irritability. The physical exam reveals conjunctivitis, strawberry tongue, inflammation of the hands and feet, desquamation of the skin of the fingers and toes, and cervical lymphadenopathy with the smallest node at 1.5 cm. The abdominal exam demonstrates tenderness and enlarged liver. Laboratory tests report elevated alanine aminotransferase, white blood cell count of 17,580/mm, albumin 2.1 g/dL, C-reactive protein 4.5 mg, erythrocyte sedimentation rate 60 mm/h, mild normochromic, normocytic anemia, and leukocytes in urine of 20/mL with no bacteria identified. The echocardiogram shows moderate dilation of the coronary arteries with possible coronary artery aneurysm.

Clinical trial eligibility criteria: eligible ages (years): 0.0-18.0,  Kawasaki Disease The 5th revised edition of diagnostic for KD, issued by the Japan Kawasaki Disease Research Committee at the 7th International Kawasaki Disease Symposium in 2002, was adopted. Cases were included in the study if the patients had at least five of the following six clinical manifestations or at least four signs together with coronary abnormalities documented by echocardiography or coronary angiography fever persisting 5 days or longer (inclusive of those cases in whom the fever has subsided before the 5th day in response to therapy) bilateral conjunctival congestion changes of lips and oral cavity, such as reddening of lips, strawberry tongue, diffuse congestion of oral and pharyngeal mucosa polymorphous exanthema changes of peripheral extremities, such as reddening of palms and soles, indurative edema at initial stage, or membranous desquamation from fingertips at convalescent stage acute nonpurulent cervical lymphadenopathy. In addition, the cases of incomplete KD, diagnosed with referring to the guidelines for incomplete KD made by American Academy of Pediatrics (AAP) and American Heart Association (AHA) in 2004, were also included in this investigation  The cases were not in accordance with the recruited
Patient description: A 2-year-old boy is brought to the emergency department by his parents for 5 days of high fever and irritability. The physical exam reveals conjunctivitis, strawberry tongue, inflammation of the hands and feet, desquamation of the skin of the fingers and toes, and cervical lymphadenopathy with the smallest node at 1.5 cm. The abdominal exam demonstrates tenderness and enlarged liver. Laboratory tests report elevated alanine aminotransferase, white blood cell count of 17,580/mm, albumin 2.1 g/dL, C-reactive protein 4.5 mg, erythrocyte sedimentation rate 60 mm/h, mild normochromic, normocytic anemia, and leukocytes in urine of 20/mL with no bacteria identified. The echocardiogram shows moderate dilation of the coronary arteries with possible coronary artery aneurysm.

Clinical trial eligibility criteria: eligible ages (years): 0.667-18.0,  Kawasaki Disease Children Patients, male and female, at any age ≥ 8 months (10kg) of life, with KD according to the American Heart Association definition for complete or incomplete KD. fever ≥ 5 days and ≥ 4 of 5 main clinical signs: modification of the extremities, polymorphic exanthema, bilateral bulbar not exudative conjunctivitis, erythema of the lips or oral cavity, and cervical lymph nodes usually unilateral > 1.5 cm in diameter. In the presence of less than 4 clinical and 5 days of fever, the diagnosis of disease KD is proposed in case of coronary abnormalities (at least one dilated coronary artery with internal diameter ≥ 2,5 SD from the mean normalized for body surface area (Z score) as determined by echocardiography. For indicative purpose, in case of incomplete KD, other biological supportive for incomplete KD can help to ensure the diagnosis: leucocytosis, elevated CRP, elevated ESR, anaemia, hyponatremia, elevated ASAT, ALAT and gGT, hyperlipidaemia Patients who failed to respond to standard therapy of KD:, e.g. Persistence or recrudescence of fever ≥ 38°C, 48 hours after the infusion of 2g/kg of IV Ig Weight ≥10Kg Patient, parent or legal guardian's written informed consent is required Patient with health insurance Patient agrees to have effective contraception for the duration of participation in the research  Preterm and neonates, pregnancy Patients suspected with another diagnosis Patients with overt concomitant bacterial infection Patients previously treated with another biotherapy Patients with any type of immunodeficiency or cancer Patients with increased risk of TB infection Recent tuberculosis infection or with active TB Close contact with a patient with TB Patients recently arrived less than 3 months from a country with high prevalence of TB A chest radiograph suggestive of TB
Patient description: A 2-year-old boy is brought to the emergency department by his parents for 5 days of high fever and irritability. The physical exam reveals conjunctivitis, strawberry tongue, inflammation of the hands and feet, desquamation of the skin of the fingers and toes, and cervical lymphadenopathy with the smallest node at 1.5 cm. The abdominal exam demonstrates tenderness and enlarged liver. Laboratory tests report elevated alanine aminotransferase, white blood cell count of 17,580/mm, albumin 2.1 g/dL, C-reactive protein 4.5 mg, erythrocyte sedimentation rate 60 mm/h, mild normochromic, normocytic anemia, and leukocytes in urine of 20/mL with no bacteria identified. The echocardiogram shows moderate dilation of the coronary arteries with possible coronary artery aneurysm.

Clinical trial eligibility criteria: eligible ages (years): 0.083-12.0,  Kawasaki Disease Individual patient's medical file data confirmed the diagnosis of KD using the 5th revised edition of diagnostic for KD, issued by the Japan Kawasaki Disease Research Committee at the 7th International Kawasaki Disease Symposium in 2002 the patients aged from 1 months to 12 years old All included patients required to sign an informed consent form the patients didn't receive treatment before  The patients with the application of hormone or other immunosuppressive agents The patients didn't want to signed informed consent
Patient description: A 2-year-old boy is brought to the emergency department by his parents for 5 days of high fever and irritability. The physical exam reveals conjunctivitis, strawberry tongue, inflammation of the hands and feet, desquamation of the skin of the fingers and toes, and cervical lymphadenopathy with the smallest node at 1.5 cm. The abdominal exam demonstrates tenderness and enlarged liver. Laboratory tests report elevated alanine aminotransferase, white blood cell count of 17,580/mm, albumin 2.1 g/dL, C-reactive protein 4.5 mg, erythrocyte sedimentation rate 60 mm/h, mild normochromic, normocytic anemia, and leukocytes in urine of 20/mL with no bacteria identified. The echocardiogram shows moderate dilation of the coronary arteries with possible coronary artery aneurysm.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Cirrhosis Coagulopathy Patients 18 and older, admitted to the hospital Patients who have clinically documented cirrhosis Patients who are coagulopathic (INR > 1.5 and/or platelets < 50,000) Patients undergoing an endoscopic procedure or neurosurgical procedure  Patients must not be pregnant Patients must not be taking any anticoagulant or antiplatelet medication (with the exception of ASA 81 mg or heparin for DVT prophylaxis) Patients must not have an active infection (per PI discretion) Patients must not have any known hemostatic disorder
Patient description: A 2-year-old boy is brought to the emergency department by his parents for 5 days of high fever and irritability. The physical exam reveals conjunctivitis, strawberry tongue, inflammation of the hands and feet, desquamation of the skin of the fingers and toes, and cervical lymphadenopathy with the smallest node at 1.5 cm. The abdominal exam demonstrates tenderness and enlarged liver. Laboratory tests report elevated alanine aminotransferase, white blood cell count of 17,580/mm, albumin 2.1 g/dL, C-reactive protein 4.5 mg, erythrocyte sedimentation rate 60 mm/h, mild normochromic, normocytic anemia, and leukocytes in urine of 20/mL with no bacteria identified. The echocardiogram shows moderate dilation of the coronary arteries with possible coronary artery aneurysm.

Clinical trial eligibility criteria: eligible ages (years): 35.0-60.0,  Cardiovascular Disease Men and women 35-60 years of age BMI ≥ 25 and ≤ 36 kg/m^2 LDL-C > 116 mg/dL Total Cholesterol below 240 mg/dL Triglycerides below 350 mg/d Non-smokers At least one of the following Systolic blood pressure 120-159 mmHg Diastolic blood pressure 80-99 mmHg  History of acute or chronic inflammatory conditions or heart disease, kidney disease, liver disease, autoimmune disorders, or thyroid disease (unless controlled by medication and blood results within the previous 6 months are provided) History of diabetes mellitus (and/or a fasting glucose > 126 mg/dL at screening) Stage II hypertension (blood pressure ≥ 160/100 mmHg) Lactation, pregnancy, or desire to become pregnant during the study Unwillingness to discontinue nutritional supplements, herbs, or vitamins, unless approved by investigator Use of medications/supplements for elevated lipids, blood pressure, or glucose Chronic use of non-steroidal anti-inflammatory or immunosuppressant medication Conditions requiring the use of steroids Unwillingness to refrain from blood donation prior to and during the study Any medical condition or abnormal laboratory value that is judged clinically significant by an investigator
Patient description: A 2-year-old boy is brought to the emergency department by his parents for 5 days of high fever and irritability. The physical exam reveals conjunctivitis, strawberry tongue, inflammation of the hands and feet, desquamation of the skin of the fingers and toes, and cervical lymphadenopathy with the smallest node at 1.5 cm. The abdominal exam demonstrates tenderness and enlarged liver. Laboratory tests report elevated alanine aminotransferase, white blood cell count of 17,580/mm, albumin 2.1 g/dL, C-reactive protein 4.5 mg, erythrocyte sedimentation rate 60 mm/h, mild normochromic, normocytic anemia, and leukocytes in urine of 20/mL with no bacteria identified. The echocardiogram shows moderate dilation of the coronary arteries with possible coronary artery aneurysm.

Clinical trial eligibility criteria: eligible ages (years): 0.0-18.0,  Blistering Distal Dactylitis Children 0-18 years Distal blistering dactylitis collected or not collected Positive rapid Group A Streptococcus test Informed consent signed by the parents  Subungual or pulp Whitlow Children not affiliated to the social security scheme Refusal by the parents to participate in the study
Patient description: A 56-year-old female on 20th day post-left mastectomy presents to the emergency department complaining of shortness of breath and malaise. The patient says that she has remained in bed for the last two weeks. The physical examination reveals tenderness on the left upper thoracic wall and right calf. The surgical incision shows no bleeding or signs of infection. Pulmonary auscultation is significant for bilateral decreased breath sounds, especially at the right base. Laboratory tests reveal an elevated D-dimer.

Clinical trial eligibility criteria: eligible ages (years): 18.0-75.0,  Lung Diseases Pulmonary Embolism Men and women suspected of having a pulmonary embolism and who met the to undergo angiography
Patient description: A 56-year-old female on 20th day post-left mastectomy presents to the emergency department complaining of shortness of breath and malaise. The patient says that she has remained in bed for the last two weeks. The physical examination reveals tenderness on the left upper thoracic wall and right calf. The surgical incision shows no bleeding or signs of infection. Pulmonary auscultation is significant for bilateral decreased breath sounds, especially at the right base. Laboratory tests reveal an elevated D-dimer.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Breast Cancer Colorectal Cancer Lung Cancer Prostate Cancer Veno-occlusive Disease Histologically or cytologically proven breast, lung, colorectal, or prostate cancer that has failed prior chemotherapy or hormone therapy No active CNS metastases Hormone receptor status: Not specified Age: 18 and over Menopausal status: Not specified Performance status: ECOG 0-2 Life expectancy: At least 12 weeks Hematopoietic: WBC at least 3500/mm3 Platelet count at least 150,000/mm3 Fibrinogen above lower limits of normal Hepatic: Bilirubin no greater than 1.5 times upper limit of normal (ULN) SGOT no greater than 3 times ULN Prothrombin time no greater than 1.5 times ULN Active partial thromboplastin time no greater than 1.5 times ULN Renal: Creatinine no greater than 1.5 times ULN Other: No history of heparin associated thrombocytopenia At least 1 year since prior thromboembolic phenomenon such as deep venous thrombosis, pulmonary embolus, or clotted catheter No prior intolerance of unfractionated or low molecular weight heparin PRIOR No concurrent anticoagulation therapy No concurrent enrollment on systemic or radiation therapy study (therapy off study allowed)
Patient description: A 56-year-old female on 20th day post-left mastectomy presents to the emergency department complaining of shortness of breath and malaise. The patient says that she has remained in bed for the last two weeks. The physical examination reveals tenderness on the left upper thoracic wall and right calf. The surgical incision shows no bleeding or signs of infection. Pulmonary auscultation is significant for bilateral decreased breath sounds, especially at the right base. Laboratory tests reveal an elevated D-dimer.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Cardiovascular Diseases Lung Diseases Pulmonary Embolism Venous Thromboembolism
Patient description: A 56-year-old female on 20th day post-left mastectomy presents to the emergency department complaining of shortness of breath and malaise. The patient says that she has remained in bed for the last two weeks. The physical examination reveals tenderness on the left upper thoracic wall and right calf. The surgical incision shows no bleeding or signs of infection. Pulmonary auscultation is significant for bilateral decreased breath sounds, especially at the right base. Laboratory tests reveal an elevated D-dimer.

Clinical trial eligibility criteria: eligible ages (years): 35.0-999.0,  Arthroplasty Patients scheduled for primary elective unilateral total hip arthroplasty (i.e. first time the hip is being replaced on the operative side) Patients who have given written informed consent to participate in this study  Patients with a contraindication to contrast venography Patients with an increased risk of bleeding Patients with a predefined risk for prethrombotic episodes or a history of thrombophilia Other or to be determined by the physician and study sponsor
Patient description: A 56-year-old female on 20th day post-left mastectomy presents to the emergency department complaining of shortness of breath and malaise. The patient says that she has remained in bed for the last two weeks. The physical examination reveals tenderness on the left upper thoracic wall and right calf. The surgical incision shows no bleeding or signs of infection. Pulmonary auscultation is significant for bilateral decreased breath sounds, especially at the right base. Laboratory tests reveal an elevated D-dimer.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Small Cell Lung Cancer Written informed consent (patient's written understanding of and agreement to participate in this study) Patients with confirmed extensive small cell lung cancer (SCLC) No prior chemotherapy within 5 years of the diagnosis of SCLC Presence of either measurable or non-measurable SCLC by X-ray or physical examination At least 3 weeks since last major surgery (a lesser period is acceptable if decided to be in the best interest of the patient) At least 24 hours since prior radiotherapy. Patients who have received radiotherapy must have recovered from any reversible side effects, such as nausea and vomiting Laboratory Patients must have adequate bone marrow reserve and adequate kidney and liver function  Symptoms of spreading of the disease to the brain that requires treatment with drugs called steroids Any active infection Severe medical problems other than the diagnosis of SCLC, that would limit the ability of the patient to follow study guidelines or that would expose the patient to extreme risk Ongoing or planned chemotherapy, immunotherapy, radiotherapy, or investigational therapy for the treatment of SCLC Use of an investigational drug within 30 days before the first dose of study medication Women who are pregnant or lactating Patients of child-bearing potential who refuse to practice an adequate form of birth control Patients with clinical evidence of any stomach or intestinal (GI) condition Patients requiring treatment with the drug cyclosporin A
Patient description: A 56-year-old female on 20th day post-left mastectomy presents to the emergency department complaining of shortness of breath and malaise. The patient says that she has remained in bed for the last two weeks. The physical examination reveals tenderness on the left upper thoracic wall and right calf. The surgical incision shows no bleeding or signs of infection. Pulmonary auscultation is significant for bilateral decreased breath sounds, especially at the right base. Laboratory tests reveal an elevated D-dimer.

Clinical trial eligibility criteria: eligible ages (years): 18.0-85.0,  Pulmonary Hypertension Cancer Lung Disease Cardiothoracic Surgery Ages 18 to 85 years old Evidence of underlying lung disease by history and physical and/or chest x-ray and/or pulmonary function testing (PFT's) PHTN documented by Doppler Echocardiography ( Done with in last 30 days) Must be able to give an informed consent  Patients with clinically significant hypotension (defined as a systolic blood pressure (SBP) <90) Active infection or sepsis as defined by fever and need for IV antibiotics Creatinine greater than 3.0 mg/dl Significant valvular disease as a cause for the PHTN Severe Thrombocytopenia (as defined by platelets less than 20,000 or INR > 1.6 Left Ventricle Ejection Fraction (LVEF) <40% (must be done with in the last 30 days prior to signing consent) Hypersensitivity to nesiritide or any of it's components
Patient description: A 56-year-old female on 20th day post-left mastectomy presents to the emergency department complaining of shortness of breath and malaise. The patient says that she has remained in bed for the last two weeks. The physical examination reveals tenderness on the left upper thoracic wall and right calf. The surgical incision shows no bleeding or signs of infection. Pulmonary auscultation is significant for bilateral decreased breath sounds, especially at the right base. Laboratory tests reveal an elevated D-dimer.

Clinical trial eligibility criteria: eligible ages (years): 18.0-85.0,  Heart Failure Cardiovascular Disease Acute Heart Failure Diastolic Heart Failure Congestive Heart Failure Heart Disease The patient population recruited for this study will patients being admitted for acute congestive heart failure. Eligible patients those who have near normal LV systolic function Age 18 to 85 years old Admitted with acute heart failure determined by: symptoms of fatigue; shortness of breath; edema; physical evidence of volume overload; and/or pulmonary edema by CXR LVEF > or = 40% on recent (< or = 1 month) echo or MUGA NYHA class III or IV on admission Baseline systolic blood pressure > 90 mm Hg Baseline BNP level > 100 pg/ml Able to sign informed consent and return for follow-up assessments  Patients with clinically significant hypotension (defined as a systolic blood pressure (SBP) <90 mm Hg) Active infection/sepsis as defined by fever > 101.5 F, currently on IV antibiotics Creatinine greater than 3.0 mg/dl LV ejection fraction < 40% (must be done within the last 30 days prior to signing consent) Significant valvular disease or constrictive cardiomyopathy Severe Thrombocytopenia (as defined by platelets less than 20,000) or INR > 1.6 Hypersensitivity to nesiritide or any of its components Pulmonary capillary wedge pressure (PCWP) <16 mmHg If patient is of child-bearing age, a pregnancy test will be performed, and the patient is excluded if pregnancy test is positive
Patient description: A 56-year-old female on 20th day post-left mastectomy presents to the emergency department complaining of shortness of breath and malaise. The patient says that she has remained in bed for the last two weeks. The physical examination reveals tenderness on the left upper thoracic wall and right calf. The surgical incision shows no bleeding or signs of infection. Pulmonary auscultation is significant for bilateral decreased breath sounds, especially at the right base. Laboratory tests reveal an elevated D-dimer.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Deep Vein Thrombosis Adult man or woman, aged ≥18 years, presenting with suspected lower-limb initial or recurrent DVT Moderate or high pre-test probability (PTP) for DVT Onset of symptoms occurred within the last 7 days Women of childbearing potential to have a negative pregnancy test as determined by measuring serum β-hCG levels at time of study enrolment  Receiving anticoagulant therapy at therapeutic doses for >3 days Life expectancy <3 months Patient with a renal transplant Renal dysfunction: serum creatinine >1.5x upper limit of normal range Hepatic dysfunction: serum transaminases >3x upper limit of normal range Current pregnancy or lactation; or conception intended within 90 days of enrolment Of childbearing potential and unwilling to use adequate contraception for 30 days following enrolment Unable to undergo lower limb ascending venography on symptomatic leg(s) Allergy or other contraindication to intravenous contrast dye Prior exposure to murine or humanized antibodies
Patient description: A 56-year-old female on 20th day post-left mastectomy presents to the emergency department complaining of shortness of breath and malaise. The patient says that she has remained in bed for the last two weeks. The physical examination reveals tenderness on the left upper thoracic wall and right calf. The surgical incision shows no bleeding or signs of infection. Pulmonary auscultation is significant for bilateral decreased breath sounds, especially at the right base. Laboratory tests reveal an elevated D-dimer.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Renal Insufficiency Adult patient aged > 18 years Admitted to an ICU with an expected ICU length of stay > 72 hours Severe renal insufficiency, defined by a calculated CrCl < 30 mL/min/1.73m2  ICU admission for > 2 weeks at time of screening ICU admission within 3 months of cardiac surgery or neurosurgery Active bleeding or at high risk for bleeding complications Thrombocytopenia (platelet count < 75 x 10^9/L) at time of screening Coagulopathy (International Normalized Ratio [INR] or activated partial thromboplastin time [aPTT] > 2 times upper limit of normal) at time of screening Patient had an indwelling epidural catheter for epidural analgesia within the last 12 hours Receipt of > 2 doses of LMWH (prophylactic or therapeutic-dose) in the ICU Receiving or requiring therapeutic-dose anticoagulation (eg., deep vein thrombosis [DVT]) at time of screening Receiving dialysis that requires anticoagulation (eg., slow continuous ultrafiltration [SCUF]) at time of screening